| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
GDC-6036-NH does not have a direct biological target. It is a synthetic intermediate or precursor used in medicinal chemistry for the development of more complex molecules. The final compound (17a/b) targets RAS, a key signaling protein involved in cell proliferation and survival that is frequently mutated in cancer. As a precursor, GDC-6036-NH is used in the synthesis of the active RAS inhibitor.
|
|---|---|
| ln Vitro |
Specific in vitro activity data are not applicable for GDC-6036-NH as it is not a pharmacologically active drug. It is a chemical precursor used in organic synthesis. Its activity would depend on the final compound it is used to synthesize.
|
| ln Vivo |
Cellular assays are not applicable for GDC-6036-NH as it is not a pharmacologically active drug. It is a chemical intermediate used in research and development.
|
| Enzyme Assay |
A cell-free assay is not applicable for GDC-6036-NH as it is not a pharmacologically active drug targeting a specific enzyme or receptor.
|
| Cell Assay |
Cellular experiments are not applicable for GDC-6036-NH as it is not a pharmacologically active drug. It is a chemical intermediate used in research and development.
|
| Animal Protocol |
In vivo animal experiments are not applicable for GDC-6036-NH as it is not a pharmacologically active drug. It is a chemical intermediate used in research and development.
|
| ADME/Pharmacokinetics |
GDC-6036-NH has a molecular formula of C26H30ClF4N7O and a purity of >98%. It is a solid. For storage, the powder should be kept at -20°C for up to 3 years; in solution, it can be stored at -20°C for up to 6 months. Specific pharmacokinetic properties are not applicable as it is not a therapeutic drug.
|
| Toxicity/Toxicokinetics |
Toxicity data for GDC-6036-NH are not provided in the available sources. As a chemical intermediate, it should be handled with appropriate safety precautions. It is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
GDC-6036-NH (CAS: 2417918-80-8) is a precursor compound for the synthesis of Compound 17a/b, a RAS inhibitor. It is described in patent WO2020097537A2. The compound is used in cancer research. Its molecular formula is C26H30ClF4N7O. It is not a therapeutic drug and is strictly for research purposes as a synthetic intermediate.
|
| Molecular Formula |
C26H30CLF4N7O
|
|---|---|
| Molecular Weight |
568.009317874908
|
| Exact Mass |
567.213
|
| CAS # |
2417918-80-8
|
| PubChem CID |
146624902
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
39
|
| Complexity |
830
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1(N)=NC(C2=C(F)C3C(C=C2Cl)=C(N2CCNC[C@@H]2C)N=C(OC[C@@H]2CCCN2C)N=3)=C(C(F)(F)F)C(C)=C1
|
| InChi Key |
XPOSONRWHCKUDU-GJZGRUSLSA-N
|
| InChi Code |
InChI=1S/C26H30ClF4N7O/c1-13-9-18(32)34-23(20(13)26(29,30)31)19-17(27)10-16-22(21(19)28)35-25(39-12-15-5-4-7-37(15)3)36-24(16)38-8-6-33-11-14(38)2/h9-10,14-15,33H,4-8,11-12H2,1-3H3,(H2,32,34)/t14-,15-/m0/s1
|
| Chemical Name |
6-[6-chloro-8-fluoro-4-[(2S)-2-methylpiperazin-1-yl]-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-7-yl]-4-methyl-5-(trifluoromethyl)pyridin-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~250 mg/mL (~440.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7605 mL | 8.8027 mL | 17.6053 mL | |
| 5 mM | 0.3521 mL | 1.7605 mL | 3.5211 mL | |
| 10 mM | 0.1761 mL | 0.8803 mL | 1.7605 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
